{"product_id":"sulanda-surufatinib","title":"SULANDA  (Surufatinib)","description":"\u003cp\u003eSurufatinib is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with vascular endothelial growth factor receptors (VEGFR) and fibroblast growth factor receptor (FGFR), which both inhibit angiogenesis, and colony stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated macrophages, promoting the body’s immune response against tumor cells. Its unique dual mechanism of action may be very suitable for possible combinations with other immunotherapies, where there may be synergistic anti-tumor effects.\u003c\/p\u003e\u003cul\u003e\u003cli\u003eSurufatinib sold as brand name 苏泰达® (SULANDA) in china.\u003c\/li\u003e\u003c\/ul\u003e\u003cp\u003eIn China,Surufatinib being approved in China in June 2021 and December 2020 for pNETs and epNETS.\u003c\/p\u003e\u003cp\u003e \u003c\/p\u003e","brand":"HUTCHMED, China","offers":[{"title":"Default Title","offer_id":44797957275691,"sku":"RL3220250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-01-1884.jpg?v=1787022279","url":"https:\/\/xomeds.com\/products\/sulanda-surufatinib","provider":"XOMEDS","version":"1.0","type":"link"}